BG
TVTX icon

Bellevue Group’s Travere Therapeutics TVTX Stock Holding History

Bellevue Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$392K Sell
6,908
-1,991
-22% -$88.3K 0.01% 117
2026
Q1 		$264K Buy
8,899
+5,072
+133% +$152K 0.01% 128
2025
Q4 		$146K Buy
+3,827
New +$124K ﹤0.01% 157
2025
Q3 		– Sell
-18,303
Closed -$271K – 157
2025
Q2 		$271K Sell
18,303
-4,797
-21% -$79.5K 0.01% 118
2025
Q1 		$414K Hold
23,100
– – 0.01% 122
2024
Q4 		$402K Sell
23,100
-7,900
-25% -$140K 0.01% 128
2024
Q3 		$434K Buy
+31,000
New +$323K 0.01% 133

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group's TVTX Position: Q2 2026 in Review

Bellevue Group reduced its Travere Therapeutics (TVTX) stake by 22% in Q2 2026, selling an estimated $88.3K and leaving 6,908 shares worth $392K. The position accounts for 0.01% of the portfolio, ranked #117.

Bellevue Group first reported a position in TVTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $434K in Q3 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Bellevue Group held 6,908 shares of Travere Therapeutics worth $392K as of Q2 2026.
  • Bellevue Group sold 1,991 Travere Therapeutics shares in Q2 2026, an estimated $88.3K.
  • Travere Therapeutics made up 0.01% of Bellevue Group's portfolio in Q2 2026, its #117 holding.
  • Bellevue Group first reported a position in Travere Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Bellevue Group's Travere Therapeutics position peaked at $434K in Q3 2024.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.